Sustainability

CHPA logo and graphics with text reading Sustainability Spotlight

CHPA is committed to promoting best practices that seek to minimize environmental impacts, without compromising on health outcomes, product safety, and access to consumers. How do our members fulfill this responsibility? Whether that’s a reduction in plastics in packaging wherever feasible, reducing carbon footprint, working with partners across the value chain to innovate packaging solutions and improve recycling infrastructure, or other efforts, CHPA’s new Sustainability Spotlight will periodically highlight the important strides our manufacturer companies are making towards sound environmental stewardship.

To submit your sustainability story for inclusion, contact Carla Stillwagon.

For more information on CHPA’s state advocacy efforts surrounding sustainability, contact Carlos Gutierrez.

Current Sustainability Spotlight

This week's spotlight, Bayer: In aiming to achieve its goals of being climate neutral by 2030 and net zero by 2050, Bayer’s Consumer Health Division says it is prioritizing “reduce, recycle, reuse and replace” across its products and packaging. 

Read More

Browse Sustainability Content

Blue United States on light blue background
State Government Reports

View members-only reports outlining progress on CHPA state legislative priorities.

A picture of generic OTC medicines
Drug Take-Back in the States

CHPA opposes mandatory manufacturer-funded drug take-back programs as they threaten the affordability of OTC medications that consumers rely on as the first line of defense against common ailments.

Test tubes lying on their sides
Green Chemistry

CHPA encourages state and local lawmakers to refrain from creating new legislation addressing green chemistry in pharmaceuticals, and instead rely on the rigorous guidelines and standards already implemented at the federal level by agencies like the FDA.

Microplastics Under a Magnifying Glass
PFAS (Per-and Polyfluoroalkyl Substances) in the States

Though rising PFAS levels prompt important health questions that must be monitored, restrictions should remain grounded in conclusive toxicology to avoid reactionary bans on safe modern alternatives — as inconsistent standards across 50 individual states would only stifle healthcare advancement.

Filter Results